631 results
-
List item
Herbal medicinal product: Vitis viniferae folium
Vitis vinifera L., Grapevine Leaf, F: Assessment finalised, Last updated: 05/01/2018Vitis viniferae folium Circulatory … Vitis viniferae folium … public Grapevine leaf Vitis vinifera L., folium This … -
List item
National expert: Marcos Timón, The Spanish Agency Of Medicines And Medical Devices (updated)
- Declaration of interests - 80.27 KB | PDF
- Curriculum Vitae - 24.19 KB | PDF
Marcos Timón … Marcos Timón … Vitae PERSONAL INFORMATION Marcos Timon WORK EXPERIENCE August … -
List item
National expert: Marco Franceschin, Italian Medicines Agency (updated)
- Declaration of interests - 79.79 KB | PDF
- Curriculum Vitae - 27.99 KB | PDF
Marco Franceschin … Marco Franceschin … Vitae PERSONAL INFORMATION Marco Franceschin WORK EXPERIENCE June … -
List item
National expert: Marco Vincenzo Patruno, Ministry Of Health (updated)
- Declaration of interests - 79.8 KB | PDF
- Curriculum Vitae - 30.38 KB | PDF
Marco Vincenzo Patruno … Marco Vincenzo Patruno … Vitae PERSONAL INFORMATION Marco Vincenzo Patruno WORK EXPERIENCE January … -
List item
National expert: Marco van Teijlingen, Medicines Evaluation Board (updated)
- Declaration of interests - 79.83 KB | PDF
- Curriculum Vitae - 16.52 KB | PDF
Marco van Teijlingen … Marco van Teijlingen … Vitae PERSONAL INFORMATION Marco van Teijlingen WORK EXPERIENCE November … -
List item
National expert: Marco Di Girolamo, Italian Medicines Agency (updated)
- Declaration of interests - 79.78 KB | PDF
- Curriculum Vitae - 17.92 KB | PDF
Marco Di Girolamo … Marco Di Girolamo … Vitae PERSONAL INFORMATION Marco Di Girolamo WORK EXPERIENCE … -
List item
National expert: Marco Panero Bertucci, The Spanish Agency Of Medicines And Medical Devices (updated)
- Declaration of interests - 79.83 KB | PDF
- Curriculum Vitae - 19.12 KB | PDF
Marco Panero Bertucci … Marco Panero Bertucci … Vitae PERSONAL INFORMATION Marco Panero Bertucci WORK EXPERIENCE January … -
List item
National expert: Karl de Marco, Medicines Authority (updated)
- Declaration of interests - 79.78 KB | PDF
- Curriculum Vitae - 17.85 KB | PDF
Karl de Marco … Karl de Marco … Vitae PERSONAL INFORMATION Karl de Marco WORK EXPERIENCE January … -
List item
National expert: Marco Antônio de Ávila Vitória, European Medicines Agency (updated)
- Declaration of interests - 79.83 KB | PDF
- Curriculum Vitae - 29.25 KB | PDF
Marco Antônio de Ávila Vitória … Marco Antônio de Ávila Vitória … Vitae PERSONAL INFORMATION Marco Antonio de Avila Vitoria WORK … -
List item
Summary of opinion: Opzelura (new)
ruxolitinib, opinion date: 23/02/2023, Positive, Last updated: 24/02/2023treatment of non-segmental vitiligo. The applicant for this A … condition in non-segmental vitiligo as measured by improvement … depigmentation from baseline on the Vitiligo Area Scoring Index (F-VASI75 … -
List item
Human medicine European public assessment report (EPAR): Opdualag
nivolumab, Relatlimab, Melanoma
Date of authorisation: 15/09/2022,
, Authorised, Last updated: 17/10/2022
-
List item
National expert: Valeria Dusolina Di Giorgi Gerevini, Italian Medicines Agency (updated)
- Declaration of interests - 79.82 KB | PDF
- Curriculum Vitae - 21.84 KB | PDF
Alessandra Bez, Dario Ponti, Marco Onofri, Francesco Vitello … Caruso A., Cappuccio I., Ricci Vitiani L., Romeo S., Della Rocca … -
List item
Orphan designation: Recombinant human insulin-like growth factor-I, recombinant human insulin-like growth factor binding protein-3 for: Treatment of type B extreme insulin resistance syndrome
Date of designation: 20/10/2004, Withdrawn, Last updated: 20/02/2009syndrome, alopecia areata, vitiligo, arthritis, nephritis, primary … syndrome, alopecia areata, vitiligo, arthritis, nephritis, primary … -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Ruxolitinib (phosphate)
Decision type: P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
Therapeutic area: Dermatology
PIP number: EMEA-002618-PIP02-20, Route(s) of administration: Cutaneous use, Pharmaceutical form(s): Cream
Decision date: 16/04/2021, Last updated: 13/01/2022, Compliance check: Xindication(s) Treatment of vitiligo Route(s) of administration … Condition(s): Treatment of vitiligo Pharmaceutical form(s … Condition: Treatment of vitiligo The waiver applies to … -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Zuretinol (acetate)
Decision type: PM: decision on the application for modification of an agreed PIP
Therapeutic area: Ophthalmology
PIP number: EMEA-001453-PIP01-13-M01, Route(s) of administration: Oral use, Pharmaceutical form(s): Oral solution
Decision date: 05/10/2016, Last updated: 24/11/2016, Compliance check: XOphthalmics (UK) Ltd E-mail: marco@retinagenix.com Tel. +1 7863 5214 99 PM … -
List item
Orphan designation: Aganirsen for: Treatment of central retinal vein occlusion
Date of designation: 10/06/2014, Positive, Last updated: 10/07/2014Fax +33 155 6012 56 E-mail: marconi@voisinconsulting.com For contact details of patients’ … 33 155 6012 56 E-mail: marconi@voisinconsulting.com For contact details … -
List item
Instrument for Pre-accession Assistance project 2011-2013
Last updated: 22/02/201301/01/2009 Generic Contact point marco.capellino@ema.europa.eu …
-
List item
National expert: Giuseppe Costante, Federal Agency for Medicines and Health Products (updated)
- Declaration of interests - 80.3 KB | PDF
- Curriculum Vitae - 51.84 KB | PDF
G., BARBERA C., MELLUSO R., MARCOCCI C., CHIOVATO L., DE LUCA … -
List item
Public stakeholder meeting: approval, safety monitoring and impact of COVID-19 vaccines in the EU
Virtual meeting, 13:00 - 15:15 (CET), 26/03/2021, Last updated: 14/04/2021COVID-19 vaccines in the EU, Marco Cavaleri (EMA … COVID-19 vaccines in the EU Marco Cavaleri (Head of Biological … COVID-19 vaccines in the EU Dr. Marco Cavaleri Head of Biological … -
List item
Public stakeholder meeting: development and authorisation of safe and effective COVID-19 vaccines in the EU
Virtual meeting, 11/12/2020, Last updated: 11/12/2020COVID-19 vaccines developed? (Marco Cavaleri) PDF icon application/pdf … COVID-19 vaccines developed? Marco Cavaleri (Head of Biological … vaccines developed? Dr. Marco Cavaleri Head of Biological … -
List item
Reinforcing communication with patients and healthcare professionals
Belgrade, Serbia, 23/06/2014, Last updated: 08/07/201408/07/2014 Generic Contact point marco.capellino@ema.europa.eu … -
List item
News: Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 20 - 23 February 2023 (new)
CHMP, Last updated: 24/02/2023treatment of non-segmental vitiligo, a skin disorder characterised … -
List item
EMA regular press briefing on COVID-19
Online, 15:00 - 15:30 Amsterdam time (CEST), 07/07/2022, Last updated: 07/07/2022COVID-19 activities. Speakers: Marco Cavaleri, Head of Health … -
List item
National expert: Vilma Petrikaite , State Medicines Control Agency (updated)
- Declaration of interests - 80.88 KB | PDF
- Curriculum Vitae - 30.03 KB | PDF
Proanthocyanidins from Vaccinium vitis-idaea L. Leaves: Perspectives … Raudone L. Exploring Vaccinium vitis-idaea L. as a potential source … -
List item
Press briefing on EU recommendation for COVID-19 Vaccine AstraZeneca
Virtual meeting, 29/01/2021, Last updated: 29/01/2021Sabine Straus (PRAC Chair) Marco Cavaleri (Head of Biological …